|
Biomarker
|
Cut-point
|
95% CI
|
|---|
|
Lower
|
Upper
|
|---|
|
Aβ1–42 (pg/mL)
|
< 529.0
|
479.0
|
647.0
|
|
T-tau (pg/mL)
|
> 312.0
|
261.0
|
391.0
|
|
T-tau/Aβ1–42 ratio
|
> 0.64
|
0.52
|
1.01
|
|
P-tau (pg/L)
|
> 48.9
|
42.4
|
58.7
|
|
AβX-42/X-40
|
< 0.060
|
0.055
|
0.088
|
|
APPβ (ng/mL)
|
> 136.4
|
115.3
|
144.6
|
|
NFL (ng/L)
|
< 1877.0
|
609.8
|
3149.6
|
- *For a set sensitivity of 85%, given that AD is always set as the ‘case’ in any comparison, the optimal cut-point for any specific biomarker is the same regardless of which other diagnostic group is being used as the comparator; it is the specificity that changes for different comparators
- Aβ amyloid beta, AD Alzheimer’s disease, APP amyloid precursor protein, CI confidence interval, NFL neurofilament light chain, P-tau phosphorylated tau, T-tau total tau
